О вагинитах, флоре и фауне
Rev Latinoam Microbiol 1999 Jan-Mar;41(1):25-34
Bacterial vaginosis a "broad overview".
Gonzalez Pedraza Aviles A, Ortiz Zaragoza MC, Irigoyen Coria A.
C. S. C. Dr. Jose Castro Villagrana, Departamento de Medicina Familiar, Facultad de Medicina, UNAM, Instituto de Servicios de Salud del Distrito Federal, Mexico D. F.
Bacterial vaginosis (BV) was first reported in 1995 by Gardner and Dukes, who described the unique clinical signs and symptoms and the distinctive nature of the vaginal discharge associated with it. They also described a "new" causative organism, which they named "Haemophilus vaginalis", subsequently renamed Gardnerella vaginalis. BV is currently the most prevalent cause of infectious vaginitis among women attending for genitourinary diseases. BV has a complex microbiology. Lactobacillus populations, which are usually dominant in healthy women, are replaced by a polymicrobial group of organisms that includes G. vaginalis, anaerobic Gram-negative rods such as Prevotella species, Peptostreptococcus species, Mycoplasma hominis, Ureaplasma urealyticum, and often Mobiluncus species. Anaerobic bacteria produce enzymes, aminopeptidases, that degrade protein and decarboxylases that convert amino acids and other compounds to amines. Those amines contribute to the signs and symptoms associated with the syndrome, raising the vaginal pH and producing a discharge odor. The excessive amounts of bacteria characteristic of the syndrome attach to epithelial cell surfaces, resulting in "clue cell". Nearly half the patients report no noticeable symptoms, but many develop a characteristic copious, malodorous discharge if untreated. Results from epidemiologic studies have associated BV with serious upper genital tract infections and adverse pregnancy outcome. In particular, the presence of BV in pregnant women increases the risk of preterm delivery, and evidence is now compelling that BV is a cause of preterm delivery. The interest in potential invasiveness of G. vaginalis has increased. However, virulence determinants have not been studied enough. The most important therapy includes clindamycin and metronidazole.
Об использовании Солкотриховака в детской практике курации вагинозов также ничего обнаружить не удалось, но тк он(а) состоит из лиофилизата Lactobacillus acidophilus, то вероятно этот микроорганизм в любом виде (аналогочный препарат любого неотечественного производителя, йогурт с Lb a) может быть применен с долей определенного успеха в комплексном лечении и противорецидивном лечении.
Gynakol Rundsch 1991;31(3):153-60 [Vaccination against nonspecific bacterial vaginosis. Double-blind study of Gynatren]
Siboulet A.
Institut Alfred Fournier, Paris, Frankreich.
167 patients suffering from nonspecific bacterial vaginoses were vaccinated in a double-blind, randomized, placebo-controlled trial. It appeared, during the study period of 14 months, that the vaccination with Gynatren, a lactobacillus vaccine, was significantly better than the placebo as concerns its therapeutical effect, but mainly as concerns its preventive effect (less reinfections). The vaccine was very well tolerated. We conclude that vaccination with Gynatren is an effective measure to prevent recurrences of nonspecific vaginosis.
Gynecol Obstet Invest 1988;26(3):240-9 Bacterial vaginitis: protection against infection and secretory immunoglobulin levels in the vagina after immunization therapy with Gynatren.
Ruttgers H.
University Women's Hospital, Heidelberg, St. Antonius Women's Hospital, Wuppertal, FRG.
In a prospective, randomized double-blind study the prophylactic effect of the immunotherapeutic agent, Gynatren, against reinfection was investigated in 192 patients with bacterial vaginitis (95 treated with the active preparation versus 97 with placebo). In 30 and 25% of the patients in the two groups, respectively, it was the third or even more frequent infection in a period of 12 months. In a further 46 and 39%, respectively, it was the second infection in the course of a year. All the patients were given local treatment with tetracycline-amphotericin B vaginal suppositories and at the same time vaccinated with Gynatren or placebo. One month after the start of treatment, 85% of the patients in the active-treatment group and 83% in the placebo group were asymptomatic and free from pathogenic bacteria. After 3 months 78% in the active-treatment group and 60% in the placebo group were free from infection. After 6 months 76 and 40%, and after 12 months 75 and 37% of the women in the active-treatment and placebo groups, respectively, were free from clinical symptoms and pathogenic bacteria. These results correlated with the concentrations of local antibodies (secretory immunoglobulin) detectable in the vaginal secretion.
Sex Transm Dis 1992 May-Jun;19(3):146-8
Treatment of bacterial vaginosis with lactobacilli.
Hallen A, Jarstrand C, Pahlson C.
Department of Dermatology and Venereology, University Hospital, Uppsala, Sweden.
60 women with bacterial vaginosis were entered into a double blind, placebo-controlled treatment trial with lyophilized Lactobacillus acidophilus. The lactobacilli used were producing H2O2. Immediately after completion of treatment, 16 out of 28 women who were treated with lactobacilli had normal vaginal wet smear results, in comparison to none of the 29 women treated with placebo. All women harboured Bacteroides at inclusion. Bacteroides was eliminated from the vagina of 12 out of 16 healthy women after treatment. Only three of the women who received the Lactobacillus suppository were free of bacterial vaginosis after the subsequent menstruation.